Protagonist Therapeutics, Inc (PTGX) stock
PTGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 12/30199% above fair value
$124.67−0.16 (-0.13%)
Close on Nov 17, 2026Market cap $8.07BP/E 121.0Yield –
Protagonist Therapeutics EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
Protagonist Therapeutics's EV/EBITDA was 132.6× on Nov 11, 2026, against 84.3× a year earlier. Over the last 2 years it ranged from 7.4× to 251.8×, with a median of 84.3×.
EV/EBITDA at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 132.6× | −111.0 |
| 2025 | Dec 31, 2025 | 243.5× | +231.4 |
| 2024 | Dec 31, 2024 | 12.2× | – |
See a number that looks wrong?